EP1335711B1 - Transdermal device - Google Patents

Transdermal device Download PDF

Info

Publication number
EP1335711B1
EP1335711B1 EP01968531A EP01968531A EP1335711B1 EP 1335711 B1 EP1335711 B1 EP 1335711B1 EP 01968531 A EP01968531 A EP 01968531A EP 01968531 A EP01968531 A EP 01968531A EP 1335711 B1 EP1335711 B1 EP 1335711B1
Authority
EP
European Patent Office
Prior art keywords
agent
skin
healing
transdermal flux
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01968531A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1335711A2 (en
Inventor
Weiqi Lin
Michel J. N. Cormier
Peter E. Daddona
Juanita A. Johnson
James A. Matriano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of EP1335711A2 publication Critical patent/EP1335711A2/en
Application granted granted Critical
Publication of EP1335711B1 publication Critical patent/EP1335711B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Definitions

  • This invention relates to inhibiting a decrease in the transdermal flux of an agent by inhibiting pathway closure.
  • this invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).
  • Drugs are most conventionally administered either orally or by injection. Unfortunately, many medicaments are completely ineffective or of radically reduced efficacy when orally administered since they either are not absorbed or are adversely affected before entering the blood stream and thus do not possess the desired activity. On the other hand, the direct injection of the medicament into the blood stream, while assuring no modification of the medicament in administration, is a difficult, inconvenient and uncomfortable procedure, sometimes resulting in poor patient compliance. Transdermal drug delivery offers improvements in these areas. However, in many instances, the rate of delivery or flux of many agents via the passive transdermal flux is too limited to be therapeutically effective.
  • Electrotransport refers generally to the passage of a beneficial agent, e.g., a drug or drug precursor, through a body surface, such as skin, mucous membranes, nails, and the like where the agent is induced or enhanced by the application of an electrical potential.
  • a beneficial agent e.g., a drug or drug precursor
  • the electrotransport of agents through a body surface may be attained in various manners.
  • One widely used electrotransport process, iontophoresis involves the electrically induced transport of charged ions.
  • Electroosmosis another type of electrotransport process, involves the movement of a solvent with the agent through a membrane under the influence of an electric field.
  • Electroporation still another type of electrotransport, involves the passage of an agent through pores formed by applying a high voltage electrical pulse(s) to a membrane. In many instances, more than one of these processes may be occurring simultaneously to a different extent. Accordingly, the term "electrotransport” is given herein its broadest possible interpretation, to include the electrically induced or enhanced transport of at least one charged or uncharged agent, or mixtures thereof, regardless of the specific mechanism or mechanisms by which the agent is actually being transported. Electrotransport delivery generally increases agent flux during transdermal delivery.
  • Another method of increasing the agent flux involves pretreating the skin with, or co-delivering with the beneficial agent, a skin permeation enhancer.
  • a permeation enhancer substance when applied to a body surface through which the agent is delivered, enhances its flux therethrough such as by increasing the permselectivity and/or permeability of the body surface, creating hydrophilic pathways through the body surface, and/or reducing the degradation of the agent during transport. This methodology is typically used when the drug is delivered transdermally by passive diffusion.
  • the piercing elements disclosed in these references generally extend perpendicularly from a thin, flat member, such as a pad or sheet.
  • the piercing elements or microprotrusion in some of these devices are extremely small, some having dimensions (i.e., length and width) of only about 25 - 400 ⁇ m and a microprotrusion thickness of only about 5-50 ⁇ m. These tiny piercing/cutting elements make correspondingly small microslits/microcuts in the stratum corneum for enhanced transdermal agent delivery therethrough.
  • the enhancement in transdermal agent flux provided by these pathways is completely eliminated within several hours of making the pathways.
  • a method which can prevent, or at least delay the skin's natural healing processes in order to allow transdermal flux of agents, through microcuts/microslits over longer periods of time (e.g., longer than about one hour) when the delivery methodology utilizes micropiercing elements.
  • the present invention fulfills this and related needs.
  • This invention is directed to a device for inhibiting a decrease in the transdermal flux of an agent which is being transdermally delivered or sampled over a prolonged period of time where the transdermal flux involves disrupting at least the stratum corneum layer of the skin.
  • the transdermal flux involves disrupting at least the stratum corneum layer of the skin.
  • the device of the present invention pierces, cuts or otherwise disrupts (e. g., by abrasives or tape stripping) at least the stratum corneum layer of the skin. More preferably, the device of the present invention comprises a plurality of microprotrusions which can penetrate the stratum corneum of the skin to form a plurality of pathways through which the first agent and the anti-healing agent pass.
  • the anti-healing agent(s) is delivered either before the first agent is delivered or sampled; or before and during the transdermal flux of the first agent; or during the transdermal flux of the first agent; or during and after the transdermal flux of the first agent.
  • this invention is directed to a device for causing the transdermal flux of an agent comprising:
  • the first element of the device comprises one or more stratum corneum-piercing microprotrusions which are capable of forming microslits in the skin.
  • the microprotrusions have a length of less than 0.5 mm.
  • the microprotrusions and the reservoir are an integral element.
  • the anti-healing agent(s) is selected from the group consisting of anticoagulants, anti-inflammatory agents, agent that inhibit cellular migration, osmotic agents or a mixture thereof.
  • the anti-inflammatory agent is selected from the group consisting of hydrocortisone sodium phosphate, betamethasone sodium phosphate, and triamcinolone sodium phosphate.
  • the agent that inhibits cellular migration is selected from the group consisting of laminin and related peptides.
  • the osmotic agent is a biologically compatible salt such as sodium chloride or a neutral compound such as glucose, or a zwitterionic compound such as glycine.
  • the osmotic agent is present in a sufficiently high concentration to generate, in solution, an osmotic pressure greater than about 2000 kilopascals, preferably greater than about 3000 kilopascals.
  • the osmotic pressure is generated at 20°C.
  • the osmotic agent is a neutral compound.
  • the anticoagulant is selected from the group consisting of heparin having a molecular weight from 3000 to 12,000 daltons, pentosan polysulfate, citric acid, citrate salts such as sodium citrate, EDTA, and dextrans having molecular weight from 2000 to 10,000 daltons, aspirin or lyapolate sodium.
  • the first agent is a therapeutic agent and the device of the present invention delivers the first agent transdermally to the skin.
  • the first agent comprises a macromolecular agent.
  • the macromolecular agent selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids, and polysaccharides.
  • the first agent is selected from the group consisting of heparin having a molecular weight from 3000 to 12,000 daltons, pentosan polysulfate, citric acid, citrate salts such as sodium citrate, EDTA, and dextrans having molecular weight from 2000 to 10,000.
  • the first agent that is transdermally sampled is a body analyte.
  • the body analyte is glucose.
  • the first agent and the anti-healing agent are dry-coated on one or more of said microprotrusions.
  • the first agent is a therapeutic agent coated on said microprotrusions, wherein said device is capable of delivering said first agent transdermally into the skin.
  • the device of the present invention further includes a separate reservoir in agent transmitting relation with the skin; said reservoir comprising the anti-healing agent.
  • the device of the present invention further comprises an applicator for placing said first element of said device onto the skin in order to form said disruptions, wherein said device and said applicator are configured as a kit.
  • the device of the present invention is for use in inhibiting a decrease in transdermal flux of said first
  • the first agent and the anti-healing agent (s) are delivered transdermally by passive diffusion and/or electrotransport.
  • the polypeptides and proteins used in the present invention are selected from the group selected from desmopressin, leutinizing releasing hormone (LHRH) and LHRH analogs (e. g., goserelin, leuprolide, buserelin, triptorelin), PTH, calcitonin, interferon- ⁇ , interferon- ⁇ , interferon- ⁇ , follicle stimulating hormone (FSH), hGH, insulin, insulinotropin, and erythropoietin.
  • desmopressin e.g., goserelin, leuprolide, buserelin, triptorelin
  • PTH calcitonin
  • interferon- ⁇ interferon- ⁇
  • interferon- ⁇ interferon- ⁇
  • FSH follicle stimulating hormone
  • hGH insulin, insulinotropin, and erythropoietin.
  • the oligonucleotide used in the present invention is selected from the group consisting of ISIS 2302, ISIS 15839 and other phosphorothiolated oligonucleotides and other methoxyethylphosphorothiolated oligonucleotides and the polysaccharide is selected from the group consisting of low molecular weight heparin having a molecular weight from 3000 to 12,000 daltons and pentosan polysulfate.
  • the agent that is transdermally sampled is a body analyte.
  • the body analyte is glucose.
  • FIG. 1 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate flux.
  • FIG. 2 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate delivery.
  • FIG. 3 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate flux.
  • FIG. 4 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate delivery.
  • FIG. 5 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate delivery.
  • FIG. 6 is a graph of the effect of pathway closure inhibitors on passive transdermal pentosan polysulfate delivery.
  • FIG. 7 is a graph of the effect of pathway closure inhibitors on passive transdermal DNA delivery.
  • FIG. 8 is a schematic side view of a device for transdermally delivering or sampling an agent according to the present invention.
  • transdermal flux means the rate of passage of any agent in and through the skin of an individual or the rate of passage of any analyte out through the skin of an individual.
  • transdermal means the delivery or extraction of an agent through the skin.
  • pathway means passages formed in the stratum corneum of the skin by disrupting it which allow for enhanced transdemal flux of an agent.
  • the stratum corneum of the skin can be disrupted by methods well known in the art such as sanding, tape stripping, creating microcuts, and the like. Other methods are described in US Patents Nos. 6,022,316 , 5,885,211 and 5,722,397 the disclosures of which are incorporated herein in their entirety.
  • the passages are formed by disrupting of the skin with a device having a plurality of stratum corneum-piercing microprotrusions thereby creating microcuts in the stratum corneum.
  • microprotrusion refers to very tiny stratum corneum piercing elements typically having a length of less than 500 micrometers, and preferably less than 250 micrometer, which make a penetration in the stratum corneum. In order to penetrate the stratum corneum, the microprotrusions preferably have a length of at least 50 micrometers.
  • the microprotrusions may be formed in different shapes, such as needles, hollow needles, blades, pins, punches, and combinations thereof.
  • microprotrusion array refers to a plurality of microprotrusions arranged in an array for piercing the stratum corneum.
  • the microprotrusion array may be formed by etching a plurality of blades from a thin sheet and folding each of the blades out of the plane of the sheet to form the configuration shown in FIG. 8.
  • the microprotrusion array may also be formed in other known manners, such as by connecting multiple strips having microprotrusions along an edge of each of the strips.
  • the microprotrusion array may include hollow needles which inject a liquid formulation. Examples of microprotrusion arrays are described in U.S. Patent No.
  • WO 96/37155 discloses a percutaneous delivery or sampling device comprising a plurality of micro-blades for piercing and anchoring to the skin for increasing transdermal flux of an agent and for improving attachment of the device to the skin.
  • WO 93/17754 discloses a drug delivery device that includes a liquid reservoir for a liquid drug to be delivered, and a drug delivery body which includes a plurality of tubular elements, each having an inlet end communicating with the liquid reservoir, and an outlet end projecting from the body and engageable with the subjects skin to conduct the liquid drug delivery to the subjects skin.
  • WO 01/41864 discloses a drug delivery device that permits sustained transdermal drug delivery by placing the skin under a tension that keeps the micro-pathways open.
  • WO 00/74763 discloses a device that can be used for drug delivery, or for the withdrawal and sensing of biological fluids.
  • the device includes a plurality of hollow micro-needles attached to or integrated into a substrate, and at least one reservior (containing drug) selectable in communication with the micro-needles wherein the amount of drug administered can be altered.
  • a withdrawal or sensing micro-needle device includes micro-needles attached to or integrated into a substrate, and at least one collection chamber and or sensor in communication with the micro-needles.
  • Prolonged delivery means a period of delivery that lasts for at least half an hour, preferably between several hours to about 24 hours, more preferably between about 8 and 24 hours.
  • co-delivering means the anti-healing agent(s) is administered transdermally before the agent is delivered; before and during transdermal flux of the agent; during transdermal flux of the agent; and/or during and after transdermal flux of the agent.
  • co-sampling means the anti-healing agent(s) is administered transdermally before the agent is sampled by transdermal flux; before and during transdermal flux of the agent; during transdermal flux of the agent; and/or during and after transdermal flux of the agent.
  • agent refers to an agent, drug, compound, composition of matter or mixture thereof which provides some pharmacological, often beneficial, effect. It is intended in its broadest interpretation as any pharmaceutically-acceptable substance which may be delivered to a living organism to produce a desired, usually beneficial, effect.
  • this includes therapeutic agents in all of the major therapeutic fields including, but not limited to, anti-infectives such as antibiotics and antiviral agents; analgesics such as fentanyl, sufentanil, and buprenorphine, and analgesic combinations; anesthetics; anorexics; antiarthritics; antiasthmatic agents such as terbutaline; anticonvulsants; antidepressants; antidiabetics agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antimotion sickness preparations such as scopolamine and ondansetron; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics including gastrointestinal and urinary; anticholinergics; sympathomimetrics; xanthine derivatives; cardiovascular preparations including calcium channel blockers such as nifedipine; betaagonists such as do
  • the invention is particularly useful in the controlled delivery of peptides, polypeptides, proteins, or other macromolecules difficult to deliver transdermally because of their size.
  • macromolecular substances typically have a molecular weight of at least about 300 Daltons, and more typically, in the range of about 300 to 40,000 Daltons.
  • agent may be incorporated into the agent formulation in the method of this invention, and that the use of the term "agent” in no way excludes the use of two or more such agents or drugs.
  • the agents can be in various forms, such as free bases, acids, charged or uncharged molecules, components of molecular complexes or nonirritating, pharmacologically acceptable salts. Also, simple derivatives of the agents (such as ethers, esters, amides, etc) which are easily hydrolyzed by body pH, enzymes, etc, can be employed.
  • the agents can be in solution, in suspension or a combination of both in the drug reservoir. Alternatively, the agent can be a particulate.
  • the amount of agent employed in the delivery device will be that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired result. In practice, this will vary widely depending upon the particular agent, the site of delivery, the severity of the condition, and the desired therapeutic effect. Thus, it is not practical to define a particular range for the therapeutically effective amount of agent incorporated into the method.
  • agent refers to body analytes to be sampled.
  • analyte means any chemical or biological material or compound suitable for passage through a biological membrane by the technology taught in this present invention, or by technology previously known in the art, of which an individual might want to know the concentration or activity inside the body.
  • Glucose is a specific example of an analyte because it is a sugar suitable for passage through the skin, and individuals, for example those having diabetes, might want to know their blood glucose levels.
  • Other examples of analytes include, but are not limited to, such compounds as sodium, potassium, bilirubin, urea, ammonia, calcium, lead, iron, lithium, salicylates, alcohol, licit substances, illicit drugs, and the like.
  • therapeutic amount or rate refer to the amount or rate of the agent needed to effect the desired pharmacological, often beneficial, result.
  • passive transdermal delivery is used herein to describe the passage of an agent through a body surface, eg, skin by passive diffusion.
  • passive delivery devices have a drug reservoir which contains a high concentration of a drug. The device is placed in contact with a body surface for an extended period of time, and is allowed to diffuse from the reservoir and into the body of the patient, which has a much lower concentration of drug.
  • the primary driving force for passive drug delivery is the concentration gradient of the drug across the skin. In this type of delivery, the drug reaches the bloodstream by diffusion through the dermal layers of the body.
  • the preferred agents for passive delivery are hydrophobic non-ionic agents, given that the drug must diffuse through the lipid layers of the skin.
  • electrotransport is used herein to describe the passage of a substance, eg, a drug or prodrug, through a body surface or membrane, such as the skin, mucous membranes, or nails, induced at least partially by the application of an electric field across the body surface (eg, skin).
  • a widely used electrotransport process, iontophoresis involves the electrically induced transport of therapeutic agents in the form of charged ions.
  • Ionizable therapeutic agents, eg, in the form of a salt which when dissolved forms charged agent ions, are preferred for iontophoretic delivery because the charged agent ions move by electromigration within the applied electric field.
  • Electroosmosis another type of electrotransport process, involves the movement of a liquid, which liquid contains a charged and/or uncharged therapeutic agent dissolved therein, through a biological membrane (e.g., skin) under the influence of an electric field.
  • a biological membrane e.g., skin
  • electroporation Another type of electrotransport, electroporation, involves the formation of transiently-existing pores in a living biological membrane by applying high voltage pulses thereto and delivery of a therapeutic agent therethrough.
  • more than one of these processes may be occurring simultaneously to some extent.
  • electrotransport is used herein in its broadest possible interpretation to include the electrically induced or enhanced transport of at least one agent, which may be charged, ie, in the form of ions, or uncharged, or of mixtures thereof, regardless of the specific mechanisms by which the agent is actually transported.
  • anti-healing agent means an agent which alone or in combination acts to prevent or diminish skin's natural healing processes thereby preventing the closure of the pathways formed by disruptions such as microslits/microcuts in the stratum corneum of the skin.
  • suitable anti-healing agents include, but are not limited to:
  • Neutral compounds include:
  • These salts include: sodium chloride, the salt forms of acetic acid, propionic acid, glycolic acid, pyruvic acid, hydracrylic acid, lactic acid, pivalic acid, beta-hydroxybutyric acid, glyceric acid, sorbic acid, mandelic acid, atrolactic acid, tropic acid, quinic acid, glucuronic acid, gluconic acid, gulonic acid, glucoheptonic acid, benzilic acid, ammonia, monoethanolamine, diethanolamine, aminomethylpropanediol, tromethamine, triethanolamine, galactosamine and glucosamine.
  • These salts include: the salt forms of phosphoric acid, malonic acid, fumaric acid, maleic acid, succinic acid, tartronic acid, oxaloacetic acid, malic acid, alpha-ketoglutaric acid, citramalic acid, and tartaric acid.
  • These salts include: the salt forms of aconitic acid, citric acid and isocitric acid.
  • i is about 1 and the concentration at about 2000 kPa is about 0.8 M; at about 3000 kPa it is about 1.2 M.
  • Zwitterionic coumpounds include: amino acids such as glycine, alanine, proline, threonine and valine, diamino acids such as glycylglycine, buffers such as 4-morpholinepropane sulfonic acid (MOPS), (2- ⁇ [tris(hydroxymethyl) methyl]amino ⁇ -1-ethane sulfonic acid (TES), 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES), ⁇ -hydroxy-4-(2-hydroxyethyl)-1-piperazinepropane sulfonic acid monohydrate (HEPPSO), tricine, bicine, CHES and CAPS and the like.
  • MOPS 4-morpholinepropane sulfonic acid
  • TES (2- ⁇ [tris(hydroxymethyl) methyl]amino ⁇ -1-ethane sulfonic acid
  • HPES 4-(2-hydroxyethyl)-1-piperazinee
  • the range of concentration for anticoagulant agents, anti-inflammatory agents, and agents that inhibit cellular migration is between 0.1 and 10% in the formulation.
  • the major barrier properties of the skin reside with the outermost layer of the skin, i.e., the stratum corneum.
  • the inner division, i.e., the backing layers, of the epidermis generally comprises three layers commonly identified as stratum granulosum, stratum malpighii, and stratum germinativum. There is essentially little or no resistance to transport or to absorption of an agent through these layers. Therefore, in order to enhance transdermal flux, the microprotrusions used to create pathways in the body surface in accordance with the present invention need only penetrate through the stratum corneum in order for the agent to be transdermally delivered or sampled with little or no resistance through the skin.
  • the pathways created by the microslits/microcuts are quickly closed and sealed by the skin's natural healing processes. Accordingly, the enhancement in transdermal agent flux provided by these pathways is completely eliminated within several hours of making the pathways.
  • the present invention inhibits the decrease in the transdermal flux of an agent due to the pathway closure after the pathways have been made.
  • the skin is treated with a microprotusion array device to form small cuts, slits, or holes called pathways in the outermost layer of the body surface to a limited depth.
  • the microprotrusions may be formed in different shapes, such as needles, hollow needles, pins, punches, and combinations thereof.
  • An agent delivery or sampling reservoir is placed in contact with the pretreated region of the body surface to deliver or sample the agent.
  • the agent delivery or sampling reservoir contains an anti-healing agent(s) which is co-delivered with the agent. This anti-healing agent prevents or at least inhibits the pathways from closing and hence inhibits the decrease in the transdermal flux of the agent to be delivered or sampled.
  • the anti-healing agent reservoir and the agent delivery or sampling reservoir may be different reservoirs.
  • FIG. 8 illustrates a transdermal delivery or sampling patch 10 including a plurality of microprotrusions 12, a reservoir 14, an adhesive backing layer 16, and an impermeable backing layer 18.
  • the reservoir 14 has been illustrated on a skin distal side of the microprotrusions 12, it should be understood that the reservoir may also be located in other positions.
  • a reservoir 14 may be provided by a discreet layer on the skin proximal or skin distal side of the base sheet which supports the microprotrusions 12.
  • the reservoir 14 may be provided by coatings on the microprotrusions, and/or the reservoir may be provided by coatings on the other parts of the patch 10.
  • the present invention has been described as including an agent and an anti-healing agent, it should be understood that the agent and the anti-healing agent may be provided in the same reservoir or different reservoirs in the device.
  • the device of the present invention can be used in connection with agent delivery, agent sampling, or both.
  • the device of the present invention is used in connection with transdermal drug delivery, transdermal analyte sampling, or both.
  • Transdermal delivery devices for use with the present invention include, but are not limited to, passive devices, electrotransport devices, osmotic devices, and pressure-driven devices.
  • Transdermal sampling devices for use with the present invention include, but are not limited to, passive devices, reverse electrotransport devices, negative pressure driven devices, and osmotic devices.
  • the transdermal devices of the present invention may be used in combination with other methods of increasing agent flux, such as skin permeation enhancers.
  • PPS pentosan polysulfate
  • DECAD highly negatively charged compound
  • inulin a neutral polysaccharide
  • PPS, DECAD, and inulin were delivered by passive diffusion through pathways in the skin created by pretreatment with a microprotrusion array.
  • Pretreatment involves placing a microprotrusion array onto the skin with sufficient force to create a plurality of microslits/microcuts through the stratum corneum of the skin. The microprotrusion array is then removed from the skin and then some form of agent delivery device or agent reservoir is placed over the pathways in order to effect agent delivery or sampling.
  • Pretreatment was used instead of integrated system because pathway closure appears to occur more rapidly and more reproducibly following pretreatment than when the microprotrusions are left in the skin during drug delivery.
  • the concentration of PPS was below the concentration required for anticoagulant effect.
  • Microprotrusion array application was performed with an impact applicator.
  • the system applied comprised a foam double adhesive ring (diameter 3.8 cm, thickness 0.16 cm) with a 2 cm 2 reservoir in the middle containing a microprotrusion array having an area of 2 cm 2 and comprised of a stainless steel sheet having a thickness of 0.025 mm, trapezoidally shaped blades bent at an angle of approximately 90° to the plane of the sheet, the microprotrusions had a length of 545 micrometer, and a microprotrusion density of 72 microprotrusions /cm 2 . Following application, the stretching tension was released.
  • the adhesive ring was left adhered on the skin and the microprotrusion array was removed.
  • the drug formulation 350 ⁇ L was dispensed into the drug compartment and a backing membrane was applied to the adhesive outer surface of the ring to seal the system.
  • a total of six HGPs were treated with the same drug formulation. At 1 hour and 24 hours after application, the systems from 3 HGPs from each group were removed and residual drug washed from the skin.
  • the amount of drug that had penetrated during these time intervals was determined by measuring urinary excretion of radioactivity for two days following removal of the patch and corrected from the percentage excreted following iv injection (previous studies had shown that for 3 H-PPS, 3 H DECAD, and 14 C inulin, percentage excreted over two days following injection were 32%, 65% and 94%, respectively).
  • the results (Table I) show that between 1 hour and 24 hour, flux decreased by at least one order of magnitude for all drugs indicating that pathways formed by piercing of the skin by the microprotrusions had at least partially closed.
  • the skin of one flank was manually stretched bilaterally at the time of application.
  • Application of the microprotrusion array was performed with an impact applicator.
  • the system applied comprised a foam double adhesive ring (diameter 3.8 cm, thickness 0.16 cm) with a 2 cm 2 reservoir in the middle containing a microprotrusion array having an area of 2 cm 2 and comprised of a stainless steel sheet having a thickness of 0.025 mm, trapezoidally shaped blades bent at an angle of approximately 90° to the plane of the sheet.
  • the microprotrusions had a length of 545 micrometer, and a microprotrusion density of 72 microprotrusions/cm 2 . Following application, the stretching tension was released.
  • the adhesive ring was left adhered on the skin and the microprotrusion array was removed.
  • a formulation 350 ⁇ L containing the tested compound in water and optionally a gelling agent (hydroxyethylcellulose (HEC) at 2% or silica gel at 50%) was dispensed into the drug reservoir and a backing membrane was applied to the adhesive outer surface of the ring to seal the system.
  • the guinea pig received a second system containing a different formulation on the opposite site. Twenty four hours after application, three systems from each group were removed and residual formulation washed from the skin. The skin was stained with a 1 % methylene blue solution. Excess dye was thoroughly removed with 70% isopropyl alcohol pads and a picture of the site was taken.
  • citric acid, EDTA, as well as dextran 5000 were the most effective agents in preventing pathway closure.
  • the keratolytic agent salicylic acid also had an effect on pathway closure.
  • Low pH also inhibited pathway closure.
  • Surfactants anionic, cationic and nonionic, at non-irritating concentrations, had no effect. Inert agents failed to prevent pathway closure. Sites exposed to glycerol and citric acid were also stained with India ink to confirm that the pathways were open for larger sized compounds.
  • Pentosan polysulfate a highly negatively charged compound, does not penetrate the skin significantly without the use of penetration enhancers or physical disruption of the skin barrier.
  • PPS Pentosan polysulfate
  • the concentration of PPS was below the concentration required for inhibition of pathway collapse (see Table II). Therefore, at the concentration used in this experiment, PPS behaved like a drug lacking any activity on pathway closure.
  • the purpose of the experiment was to show that inhibitors of pathway collapse identified in Example 2 also improved drug flux through the skin in vivo.
  • Microprotrusion array application was performed with an impact applicator.
  • the system applied comprised a foam double adhesive ring (diameter 3.8 cm, thickness 0.16 cm) with a drug containing hydrogel having a skin contact area of 2 cm 2 in the middle containing a microprotrusion array having an area of 2 cm 2 and comprised of a stainless steel sheet having a thickness of 0.025 mm, trapezoidally shaped blades bent at an angle of approximately 90° to the plane of the sheet, the microprotrusion had a length of 545 ⁇ m, and a microprotrusion density of 72 microprotrusion/cm 2 .
  • the amount of drug penetrated during these time intervals was determined by measuring urinary excretion of tritium (previous studies had shown that in HGPs, 32% of the tritium derived from 3 H-PPS injected intravenously is excreted in urine).
  • the results, as shown in FIG.1, show that between 1 hour and 24 hours, flux decreased by about 12 fold, demonstrating pathway closure.
  • Citric acid and 1,2,6-hexanetriol inhibited this decrease in flux. Flux in the presence of 1,2,6-hexanetriol was decreased by less than 2 fold between 1 and 24 h. Total amount transported was increased about 4 and 7 folds in the presence of citric acid and 1,2,6-hexanetriol, respectively, as compared to controls as shown in FIG. 2.
  • the additive used did not modify the 45 min PPS flux, indication that they did not present permeation enhancing properties and that pathways had not significantly closed during this period.
  • citric acid and 1,2,6-hexanetriol inhibited significantly the decrease in flux. Flux in the presence of the mixture of citric acid trisodium salt and 1,2,6-hexanetriol resulted in a complete inhibition of the decrease in PPS flux observed between 45 min and 24 h. Total amounts of PPS transported are shown in FIG. 4.
  • the effect observed in the presence of 3% citric acid trisodium salt and 50% 1,2,6-hexanetriol is greater than additive. This is probably the indication that these two agents are effective on different wound healing mechanisms (citric acid is probably preventing clot formation while 1,2,6-hexanetriol is probably preventing another regeneration process such as keratinocyte migration).
  • HGPs hairless guinea pigs
  • pCMV-AYW-HBs-Mkan plasmid DNA vaccine
  • HBsAg hepatitis B surface antigen
  • microprotrusion arrays One of two configurations of microprotrusion arrays were used. Specifications of the two arrays are given in the table below. Each configuration has a total surface area of 2 cm 2 and an active total blade surface area of 1 cm 2 .
  • a microprotrusion array of the selected type was adhered to the adhesive foam and covered the bottom of the reservoir (after application, the microprotrusion array is in contact with the skin). Following application, the stretching tension was released and the microprotrusion array was left in situ.
  • a liquid formulation (90 ⁇ L) containing 3.5 mg/mL of the plasmid DNA vaccine in buffer (TRIS 5 mM pH 7.6) was dispensed into the drug reservoir and a backing membrane was applied to the adhesive outer surface of the ring to seal the system. Additional HGPs were treated in the same way, except that the formulation contained either 1 % Tween 80 or 3% citric acid trisodium salt in addition to the plasmid DNA and the Tris buffer.
  • Examples 2-6 demonstrate that drugs of interest can have their flux enhanced by co-delivery of pathway closure inhibitors.
  • compounds presenting anticoagulants properties are effective in preventing pathway collapse. If these compounds can prevent pathway collapse and therefore prolong the delivery of drug molecules, it is obvious that if they are delivered at concentrations high enough to exert locally their anticoagulant activity, they will prolong their own delivery. Delivery experiments with drugs presenting anticoagulant properties have been performed in the HGP with PPS and the phosphorothiolated oligonucleotide ISIS 2302.
  • PPS is a drug used in the management of inflammatory conditions such as interstitial cystitis
  • the phosphorothiolated oligonucleotide ISIS 2302 is an antisense drug to the mRNA coding for the ICAM1 molecule and presenting antiinflammatory properties. Both molecules are highly negatively charged compound and do not penetrate the skin significantly without the use of penetration enhancers or physical disruption of the skin barrier.
  • a total dose of 6.5 ⁇ 1.1 mg was delivered in 24 hours in the HGP from a 2 cm 2 passive pretreatment system identical to that described in Example 3 (application was performed manually, using a microprotrusion array having an area of 2 cm 2 and comprised of a stainless steel sheet having a thickness if 0.025 mm, trapezoidally shaped blades bent at an angle of approximately 90° to the plane of the sheet, the microprotrusion had a length of 430 ⁇ m, and a microprotrusion density of 190 microprotrusions/cm 2 ).
  • the dose excreted in urine (2 mg) was found to be more than 85% intact.
  • the phosphorothiolated oligonucleotide ISIS 2302 was delivered for 24 hours using a microprotrusion array with an area of 2 cm 2 , microprotrusion lengths of 480 ⁇ m and 241 microprotrusions/cm 2 .
  • the effect of drug concentration, microprotrusion array pretreatment versus integrated treatment and delivery passive versus electrotransport were evaluated. Results, summarized in Table III, demonstrate that this compound can be effectively delivered through the skin for extended periods of time, probably as a result of its anticoagulant properties.
  • Table III Transdermal Delivery of ISIS 2302 Total dose delivered (mg) Microprotrusion Pretreatment Integrated Treatment Drug conc.
  • Drugs of interest that could be delivered at therapeutic levels using the microprotrusion technology during extended periods of time (i.e. 24 hours) and without the help of adjuvant that prevent pathway collapse include all compounds presenting anticoagulants properties during local delivery and having a molecular weight greater than about 2000. These compounds include pentosan polysulfate, oligonucleotides, low molecular weight heparin, hirudin and hirudin analogs such as hirulog. It will be appreciated by those of ordinary skill in the art that the invention can be embodied in other specific forms without departing from the essential character thereof. The presently disclosed embodiments are therefore considered in all respects to be illustrative and not restrictive. The scope of the invention as indicated by the appended claims rather than the foregoing description, and all changes which come within the meaning and range of equivalence thereof are intended to be embraced therein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)
EP01968531A 2000-09-08 2001-09-06 Transdermal device Expired - Lifetime EP1335711B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23116000P 2000-09-08 2000-09-08
US231160P 2000-09-08
PCT/US2001/027551 WO2002019985A2 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure

Publications (2)

Publication Number Publication Date
EP1335711A2 EP1335711A2 (en) 2003-08-20
EP1335711B1 true EP1335711B1 (en) 2007-07-25

Family

ID=22867983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01968531A Expired - Lifetime EP1335711B1 (en) 2000-09-08 2001-09-06 Transdermal device

Country Status (24)

Country Link
US (1) US7438926B2 (no)
EP (1) EP1335711B1 (no)
JP (2) JP5507030B2 (no)
KR (1) KR100764699B1 (no)
CN (1) CN100421653C (no)
AT (1) ATE367805T1 (no)
AU (2) AU8877401A (no)
BR (1) BR0113749A (no)
CA (1) CA2422200A1 (no)
CZ (1) CZ2003687A3 (no)
DE (1) DE60129585T2 (no)
DK (1) DK1335711T3 (no)
EE (1) EE200300095A (no)
ES (1) ES2290166T3 (no)
IL (1) IL154811A0 (no)
MA (1) MA25958A1 (no)
MX (1) MXPA03002122A (no)
NO (1) NO20031071L (no)
NZ (1) NZ524646A (no)
PL (1) PL365603A1 (no)
PT (1) PT1335711E (no)
RU (1) RU2272618C2 (no)
WO (1) WO2002019985A2 (no)
ZA (1) ZA200302700B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8877401A (en) * 2000-09-08 2002-03-22 Alza Corp Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
HUP0302924A2 (en) * 2000-10-26 2003-12-29 Alza Corp Transdermal drug delivery devices having coated microprotrusions
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
EP1638523B8 (en) * 2003-06-30 2013-12-25 ALZA Corporation Formulations for coated microprojections containing non-volatile counterions
UY28398A1 (es) * 2003-07-02 2004-11-08 Alza Corp Método y parche de inmunización por disposición de microproyección
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
CA2542874A1 (en) * 2003-10-23 2005-05-12 Alza Corporation Compositions of stabilized dna for coating microprojections
BRPI0415466A (pt) 2003-10-24 2006-12-19 Alza Corp método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos
WO2005051456A2 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
CA2562932A1 (en) 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
AU2005235990A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
AU2005235075A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of fentany-based agents
TW200616660A (en) * 2004-08-11 2006-06-01 Alza Corp Apparatus and method for transdermal delivery of natriuretic peptides
WO2006055844A2 (en) 2004-11-18 2006-05-26 3M Innovative Properties Company Method of contact coating a microneedle array
AU2005306426B2 (en) * 2004-11-18 2011-04-28 3M Innovative Properties Company Masking method for coating a microneedle array
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
CN101160117A (zh) * 2005-02-16 2008-04-09 阿尔扎公司 依泊汀-基药物的透皮释放装置和方法
US20060253078A1 (en) * 2005-04-25 2006-11-09 Wu Jeffrey M Method of treating skin disorders with stratum corneum piercing device
US20070270738A1 (en) * 2005-04-25 2007-11-22 Wu Jeffrey M Method of treating ACNE with stratum corneum piercing patch
WO2007002523A2 (en) * 2005-06-24 2007-01-04 3M Innovative Properties Company Collapsible patch with microneedle array
US20070078414A1 (en) * 2005-08-05 2007-04-05 Mcallister Devin V Methods and devices for delivering agents across biological barriers
EP1948139A4 (en) * 2005-11-18 2012-04-04 3M Innovative Properties Co COATING COMPOSITIONS, COATINGS DERIVED THEREFROM, AND MICRO-NETWORKS COMPRISING SUCH COATINGS
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US8617487B2 (en) 2009-03-25 2013-12-31 Venture Lending & Leasing Vi, Inc. Saliva sample collection systems
JPWO2011010456A1 (ja) * 2009-07-24 2012-12-27 株式会社ネクスト２１ ＮＳＡＩＤｓ含有外用剤及び当該外用剤の製造方法
EP2818159A1 (de) * 2013-06-25 2014-12-31 LTS LOHMANN Therapie-Systeme AG Vorrichtung mit transdermalem therapeutischem System, Positionier- und Penetrationshilfe
US9987361B1 (en) * 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
DE102017126501A1 (de) 2017-11-10 2019-05-16 Lts Lohmann Therapie-Systeme Ag Mikronadelsystem zur Applikation eines Hepatitis-Impfstoffes
US20190231925A1 (en) * 2018-01-31 2019-08-01 Changchun Ja Biotech. Co., Ltd. Heparin sodium supported hydrogel sustained-release paster

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE25637E (en) 1964-09-08 Means for vaccinating
US3964482A (en) 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
ATE177325T1 (de) * 1994-12-09 1999-03-15 Novartis Erfind Verwalt Gmbh Transdermales system
WO1996037256A1 (en) 1995-05-22 1996-11-28 Silicon Microdevices, Inc. Micromechanical patch for enhancing the delivery of compounds through the skin
AU5740496A (en) 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
DE19525607A1 (de) 1995-07-14 1997-01-16 Boehringer Ingelheim Kg Transcorneales Arzneimittelfreigabesystem
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
DE19541260A1 (de) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
ZA975326B (en) 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
ES2200187T3 (es) 1996-07-03 2004-03-01 Altea Therapeutics Corporation Microporacion mecanica multiple de la piel o de la mucosa.
CA2265906C (en) 1996-09-17 2003-11-11 Deka Products Limited Partnership System for delivery of drugs by transport
ES2195190T3 (es) 1996-12-20 2003-12-01 Alza Corp Dispositivo y metodo para mejorar el flujo de agente transdermico.
DE19654391A1 (de) 1996-12-27 1998-07-02 Basf Ag Katalysator zur selektiven Herstellung von Propylen aus Propan
ATE365026T1 (de) * 1996-12-31 2007-07-15 Altea Therapeutics Corp Mikroporation von gewebe zur verabreichung von bioaktiven substanzen
US6918901B1 (en) * 1997-12-10 2005-07-19 Felix Theeuwes Device and method for enhancing transdermal agent flux
ATE406935T1 (de) 1997-12-11 2008-09-15 Alza Corp Vorrichtung zur verbesserung des transdermalen flusses von medikamenten
CA2313698C (en) * 1997-12-11 2008-04-15 Alza Corporation Device for enhancing transdermal agent flux
KR100572539B1 (ko) * 1997-12-11 2006-04-24 알자 코포레이션 경피성 작용제 유동률을 증진시키기 위한 장치
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
EP1086214B1 (en) 1998-06-10 2009-11-25 Georgia Tech Research Corporation Microneedle devices and methods of their manufacture
EP1180053A4 (en) * 1999-05-17 2006-11-08 Kevin S Marchitto REMOTE AND LOCAL CONTROLLED RELEASE OF PHARMACEUTICAL COMPOUNDS USING ELECTROMAGNETIC ENERGY
EP1187653B1 (en) * 1999-06-04 2010-03-31 Georgia Tech Research Corporation Devices for enhanced microneedle penetration of biological barriers
DK1239917T3 (da) * 1999-12-10 2005-08-22 Alza Corp Hudbehandlingsapparat til vedvarende transdermal medikamentlevering
DE60024312T2 (de) * 1999-12-10 2006-08-17 Alza Corp., Mountain View Transdermale Wirkstoffabgabe von makromolekularen Wirkstoffen und Vorrichtung hierfür
AU8877401A (en) * 2000-09-08 2002-03-22 Alza Corp Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
HUP0302924A2 (en) * 2000-10-26 2003-12-29 Alza Corp Transdermal drug delivery devices having coated microprotrusions
AU2003275301A1 (en) * 2002-09-30 2004-04-23 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
ES2290166T3 (es) 2008-02-16
JP2004508319A (ja) 2004-03-18
RU2272618C2 (ru) 2006-03-27
CN100421653C (zh) 2008-10-01
BR0113749A (pt) 2004-06-22
ZA200302700B (en) 2004-08-13
PL365603A1 (en) 2005-01-10
KR20030074595A (ko) 2003-09-19
PT1335711E (pt) 2007-09-05
MA25958A1 (fr) 2003-12-31
DE60129585T2 (de) 2008-04-17
DK1335711T3 (da) 2007-11-26
US20020102292A1 (en) 2002-08-01
NZ524646A (en) 2004-10-29
KR100764699B1 (ko) 2007-10-08
DE60129585D1 (de) 2007-09-06
WO2002019985A3 (en) 2002-09-06
WO2002019985A2 (en) 2002-03-14
CN1473037A (zh) 2004-02-04
JP5507030B2 (ja) 2014-05-28
JP2013256500A (ja) 2013-12-26
NO20031071L (no) 2003-05-06
EE200300095A (et) 2005-02-15
EP1335711A2 (en) 2003-08-20
MXPA03002122A (es) 2004-09-10
AU2001288774B2 (en) 2006-06-29
US7438926B2 (en) 2008-10-21
NO20031071D0 (no) 2003-03-07
CA2422200A1 (en) 2002-03-14
AU8877401A (en) 2002-03-22
IL154811A0 (en) 2003-10-31
CZ2003687A3 (cs) 2004-01-14
ATE367805T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
EP1335711B1 (en) Transdermal device
AU2001288774A1 (en) Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
US20050089554A1 (en) Apparatus and method for enhancing transdermal drug delivery
US7579013B2 (en) Formulations for coated microprojections containing non-volatile counterions
US20050106226A1 (en) Pretreatment method and system for enhancing transdermal drug delivery
US20050123507A1 (en) Formulations for coated microprojections having controlled solubility
AU2005235075A1 (en) Apparatus and method for transdermal delivery of fentany-based agents
MXPA06004531A (en) Apparatus and method for enhancing transdermal drug delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030407

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17D Deferred search report published (corrected)

Effective date: 20020906

17Q First examination report despatched

Effective date: 20041013

RTI1 Title (correction)

Free format text: TRANSDERMAL DEVICE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070824

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60129585

Country of ref document: DE

Date of ref document: 20070906

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070402935

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2290166

Country of ref document: ES

Kind code of ref document: T3

BERE Be: lapsed

Owner name: ALZA CORP.

Effective date: 20070930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070907

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080401

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20080401

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20080606

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20071025

26N No opposition filed

Effective date: 20080428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071006

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070930

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: CH

Effective date: 20080619

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: DAS PATENT IST AUFGRUND DES WEITERBEHANDLUNGSANTRAGS VOM 19.06.2008 REAKTIVIERT WORDEN.

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: A REQUEST FOR RESTORATION TO THE PRIOR STATE (ARTICLE 23 OF THE PATENTS ACT 1995) HAS BEEN FILED ON 20080610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070930

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: CH

Effective date: 20080619

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20080531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080606

NLXE Nl: other communications concerning ep-patents (part 3 heading xe)

Free format text: THE REQUEST FOR RESTORATION TO THE PRIOR STATE, AS PROVIDED FOR IN ARTICLE 23 OF THE PATENTS ACT 1995 (SEE PUBLICATION IN HEADING XE OF THE PATENT BULLETIN OF 20080801), HAS BEEN WITHDRAWN.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071026

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070906

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071031

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071001

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080930

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071025

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070906

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070907

REG Reference to a national code

Ref country code: FR

Ref legal event code: RN

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070907

BERR Be: reestablished

Owner name: ALZA CORP.

Effective date: 20090209

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080929

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090209

REG Reference to a national code

Ref country code: FR

Ref legal event code: FC

REG Reference to a national code

Ref country code: GB

Ref legal event code: S28

Free format text: APPLICATION FILED

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070906

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090306

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

BERE Be: lapsed

Owner name: ALZA CORP.

Effective date: 20090930

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: SE

Effective date: 20081219

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: GB

Ref legal event code: S28

Free format text: RESTORATION ALLOWED

Effective date: 20100608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100930

Year of fee payment: 10

Ref country code: IT

Payment date: 20100923

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100929

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090907

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110906

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60129585

Country of ref document: DE

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110906